LL-37 · Research brief

LL-37 In Vitro Research — Mechanisms and Study Design

Real Peptides Research TeamEditorial

Updated July 9, 20268 min read

54 WORDS

Short answer

Key takeaways

LL-37 operates through three mechanistically distinct pathways. Antimicrobial membrane disruption (5–50µM), immune cell chemotaxis (0.5–2µM), and wound repair via EGFR transactivation (1–5µM). With minimal overlap between concentration ranges.
Ionic strength is the single largest protocol variable affecting LL-37 antimicrobial potency; 150mM NaCl reduces bacterial killing by 80% compared to low-salt Mueller-Hinton broth, explaining why IC50 values vary 50-fold across published studies.
Serum-free culture medium allows rapid LL-37 degradation by endogenous proteases, underestimating peptide activity by 3–5× compared to 10% FBS conditions where protease inhibitors stabilise the peptide.
Bacterial biofilms embedded in extracellular DNA sequester LL-37 and neutralise antimicrobial activity. DNase I pre-treatment is required to observe biofilm disruption in vitro, a step most static culture models omit.
TFA counterions from peptide synthesis alter LL-37 net charge and reduce antimicrobial potency by 20–30%; conversion to HCl salt form before use improves reproducibility across labs but is rarely reported in methods sections.

Research published in the Journal of Immunology identified LL-37 (the only human cathelicidin) as active across bacterial killing, wound healing, and chemotaxis. Three mechanistically distinct pathways that standard antimicrobial peptides don't touch. The peptide doesn't operate through a single mode like most defensins; it shifts function based on concentration, cell type, and local pH. A 2µM dose in keratinocyte culture triggers angiogenesis signalling, while 20µM in the same model induces cytotoxicity. This concentration-dependent multimodality is why LL-37 in vitro research requires tighter protocol standardisation than most antimicrobial studies.

We've guided research teams through LL-37 protocol optimisation across multiple cell lines. The gap between reproducible findings and contradictory results comes down to three variables most methods sections omit entirely.

What is LL-37 and why does it matter for in vitro research?

LL-37 is the 37-amino-acid C-terminal fragment of human cathelicidin antimicrobial peptide (hCAP18), cleaved by proteinase 3 in neutrophils and epithelial cells. It exhibits direct antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and enveloped viruses through membrane disruption, while simultaneously modulating immune responses by binding lipopolysaccharide (LPS), recruiting neutrophils and monocytes, and inducing chemokine expression in epithelial cells. Unlike static antimicrobials, LL-37's activity shifts based on ionic strength, serum presence, and target cell state. Making it ideal for in vitro models of infection, inflammation, and tissue repair where multifunctional host defence mechanisms need to be studied in isolation.

Most peptide literature frames LL-37 as 'an antimicrobial'. Which misses the immune-modulating and wound-repair functions that operate at sub-antimicrobial doses. The rest of this piece covers the three mechanistic pathways LL-37 activates in vitro, the protocol variables that determine which pathway dominates your assay, and the cell model mismatches that explain why published IC50 values for the same bacterial strain vary by 50-fold across papers.

LL-37 Mechanisms in Cell Culture Models

LL-37 disrupts bacterial membranes through a carpet mechanism. The peptide accumulates on the outer leaflet until local concentration triggers lipid phase separation and pore formation. This differs from barrel-stave pore formers like alamethicin; LL-37 doesn't insert perpendicular to the membrane but lies parallel until threshold density forces bilayer collapse. The process is concentration-dependent and ionic-strength-sensitive. 150mM NaCl reduces antimicrobial potency by 80% compared to low-salt buffer, which is why studies using RPMI or DMEM (both high-salt media) report IC50 values 10–50× higher than those using Mueller-Hinton broth.

The immune-modulating pathway operates through formyl peptide receptor-like 1 (FPRL1) and P2X7 purinergic receptors on monocytes, neutrophils, and epithelial cells. LL-37 binding triggers MAPK and NF-κB signalling cascades that upregulate IL-8, MCP-1, and RANTES within 2–4 hours. This is the chemotactic effect that recruits immune cells to infection sites in vivo. Critically, this happens at 0.1–2µM, well below the 5–20µM required for direct bacterial killing. Most in vitro infection models using LL-37 at antimicrobial doses inadvertently activate both pathways simultaneously, conflating membrane disruption with cytokine-mediated killing.

The third pathway. Wound repair and angiogenesis. Involves EGFR transactivation and VEGF upregulation in keratinocytes and endothelial cells. LL-37 at 1–5µM induces scratch-wound closure 40% faster than control in keratinocyte monolayers, a finding replicated across multiple labs. The mechanism involves Src kinase activation and downstream ERK1/2 phosphorylation, independent of the antimicrobial or immune pathways. This is why LL-37 appears in chronic wound studies despite showing no infection present. The peptide is deficient in non-healing ulcers not because of bacterial overgrowth but because keratinocyte migration stalls without it.

Cell Line Selection and Protocol Variables

Human keratinocyte lines (HaCaT, primary NHEKs) express endogenous hCAP18 and respond to exogenous LL-37 through autocrine feedback loops. Adding synthetic LL-37 amplifies the wound-repair pathway but can also induce inflammatory cytokine release if serum is absent. Serum contains protease inhibitors (alpha-1 antitrypsin, alpha-2 macroglobulin) that stabilise LL-37 half-life; using serum-free medium for 'cleaner' mechanistic studies inadvertently allows rapid peptide degradation and underestimates activity. Studies comparing LL-37 in 10% FBS versus serum-free show 3–5× potency difference at the same nominal concentration.

Immune cell lines (THP-1 monocytes, primary human neutrophils) are the standard for chemotaxis and cytokine assays. LL-37 induces calcium flux in THP-1 cells within 30 seconds via FPRL1, followed by IL-8 secretion peaking at 4 hours. The calcium response is biphasic. An immediate spike from intracellular stores, then sustained elevation from extracellular influx. And both phases are required for full cytokine induction. Blocking extracellular calcium with EGTA cuts IL-8 production by 60%, a detail most protocols omit. Use of pre-differentiated THP-1 (PMA-treated for 48h) versus undifferentiated cells also shifts LL-37 response; differentiated cells upregulate FPRL1 expression 4-fold and show enhanced chemotaxis.

Bacterial co-culture models require matching the bacterial strain's native environment to LL-37's activity profile. Pseudomonas aeruginosa grown in low-iron conditions upregulates alginate production, which sequesters cationic peptides and reduces LL-37 killing by 70%. Staphylococcus aureus biofilms embedded in extracellular DNA bind LL-37 and neutralise it before reaching bacterial membranes. This is why LL-37 shows strong activity against planktonic S. aureus but minimal effect on 24-hour biofilms unless combined with DNase I pre-treatment. LL-37 in vitro research using static bacterial cultures overestimates in vivo efficacy where biofilm and host factors dominate.

Study Design for Reproducible LL-37 In Vitro Research

Peptide sourcing and storage determine baseline variability before any experiment begins. Synthetic LL-37 from commercial suppliers varies in purity (85–98% by HPLC) and contains trifluoroacetate (TFA) counterions from synthesis that alter net charge and membrane affinity. TFA removal by HCl salt conversion increases antimicrobial potency by 20–30% in side-by-side assays. Most published studies don't report counterion identity. Lyophilised LL-37 should be stored at -20°C in single-use aliquots; freeze-thaw cycles cause peptide aggregation that reduces activity by 15% per cycle after three freeze-thaw rounds.

Concentration verification is non-negotiable. Nominal peptide concentration (calculated from weighed powder) assumes 100% purity and complete solubilisation, neither of which holds in practice. Running a Bradford or BCA assay on your working stock catches 20–40% discrepancies between expected and actual concentration. LL-37 also binds polypropylene and polystyrene surfaces. Diluting in siliconised tubes versus standard microcentrifuge tubes yields 15–25% higher recovered concentration after 2-hour incubation, a timeframe typical for infection assays.

Buffer composition must match your mechanistic question. Mueller-Hinton broth (cation-adjusted, low-salt) is the CLSI standard for antimicrobial susceptibility testing and shows LL-37's maximum potency. RPMI-1640 or DMEM (physiological salt, bicarbonate-buffered) better approximates tissue culture conditions but reduces antimicrobial activity 5–10×. Tris and HEPES buffers at pH 7.4 maintain LL-37 stability, but phosphate buffers above 10mM chelate divalent cations required for membrane binding and cut activity by half. If your research question involves in vivo applicability, use physiological buffers despite the potency drop. The goal is predictive accuracy, not maximum effect size.

LL-37 In Vitro Research: Study Type Comparison

Study Model	Primary Endpoint	LL-37 Concentration Range	Key Protocol Variable	Bottom Line
Antimicrobial killing assay	CFU reduction (log₁₀)	5–50 µM	Ionic strength. High salt reduces potency 5–10×	Use Mueller-Hinton broth for maximum sensitivity; physiological media for in vivo relevance
Cytokine induction (ELISA)	IL-8, TNF-α, IL-1β secretion	0.5–10 µM	Serum presence. 10% FBS stabilises peptide, absence allows degradation	Sub-antimicrobial doses (1–2 µM) trigger immune signalling without cytotoxicity
Scratch-wound migration	Time to 50% closure (hours)	1–5 µM	EGFR pathway integrity. AG1478 (EGFR inhibitor) blocks effect	LL-37 accelerates keratinocyte migration independent of antimicrobial activity
Bacterial biofilm disruption	Biofilm biomass (crystal violet staining)	10–100 µM	Extracellular DNA presence. DNase I pre-treatment required for activity	Mature biofilms sequester LL-37; planktonic data overestimate biofilm efficacy
Endothelial angiogenesis (tube formation)	Tube length and branch points	2–10 µM	VEGF pathway activation. Measure VEGF mRNA at 6h post-treatment	LL-37 induces angiogenesis through VEGF upregulation, not direct endothelial effect

What If: LL-37 In Vitro Research Scenarios

What If My Antimicrobial Assay Shows No LL-37 Activity?

Check ionic strength first. If you're using RPMI, DMEM, or PBS at physiological salt concentration (150mM NaCl), you've reduced LL-37 potency by 80% compared to Mueller-Hinton broth. Switch to low-salt buffer or accept that your IC50 will be 10–50× higher than published values. Also verify peptide concentration by Bradford assay. Commercial LL-37 purity ranges from 85–98%, and if you calculated stock concentration assuming 100% purity, you're underdosing by 2–15%.

What If I See Cytotoxicity in Keratinocyte Cultures?

You're likely above 10µM LL-37 in serum-free medium. At 20µM, LL-37 induces membrane permeabilisation in eukaryotic cells, not just bacteria. The selectivity window depends on maintaining sub-10µM doses and including 5–10% serum to stabilise the peptide and reduce non-specific membrane binding. If your wound-repair assay requires higher concentrations, add serum or switch to a shorter exposure time (2–4 hours) followed by washout.

What If Freeze-Thaw Cycles Reduced My LL-37 Activity?

LL-37 aggregates after repeated freeze-thaw, forming inactive oligomers that can't insert into membranes. After three cycles, antimicrobial activity drops by 40–50%. Aliquot your peptide stock into single-use volumes (enough for one day's experiments) and store at -20°C. Thaw each aliquot once, use it, and discard the remainder. Don't refreeze. If you must store working stock, keep it at 4°C for up to one week rather than refreezing daily.

The Mechanistic Truth About LL-37 In Vitro Research

Here's the honest answer: most LL-37 in vitro research measures the wrong mechanism for the question being asked. If you're studying infection and using 20µM LL-37 in keratinocyte co-culture with bacteria, you're triggering cytokine release, EGFR transactivation, and membrane disruption simultaneously. Then attributing the bacterial reduction to antimicrobial activity alone. That's not how LL-37 works in tissue. The peptide is released at sub-micromolar concentrations in vivo, where its primary role is recruiting neutrophils and modulating inflammation, not direct bacterial killing. The membrane-disrupting activity you're measuring at 20µM is an artefact of dose escalation beyond physiological relevance. If your in vitro model uses LL-37 concentrations above 5µM and claims to model in vivo infection, you're testing a different peptide function than what operates in the wound bed.

Our team sources research-grade peptides synthesised with exact amino-acid sequencing and verified purity. The foundation for reproducible LL-37 in vitro research starts with knowing your peptide's actual concentration and counterion composition before the first assay. When protocol variables shift your IC50 by 50-fold, the peptide quality becomes the only constant you can control. Whether you're measuring antimicrobial activity, immune modulation, or tissue repair pathways, LL-37's multimodal mechanism demands tighter standardisation than most antimicrobial peptide studies require. And that precision begins with the compound itself.

If your in vitro data contradicts published findings, re-examine your buffer's ionic strength, your serum concentration, and whether your peptide stock has been freeze-thawed more than once. Those three variables account for 80% of inter-lab discrepancies in LL-37 research. The peptide works. But only when the model matches the mechanism you're trying to isolate.

Questions

Use 5–20 µM LL-37 in low-salt Mueller-Hinton broth for maximum antimicrobial activity against planktonic bacteria. If using physiological media like RPMI or DMEM, expect to need 10–50 µM due to ionic strength reducing potency by 80%. For biofilm studies, start at 50–100 µM and consider DNase I pre-treatment to remove extracellular DNA that sequesters the peptide.

LL-37 working stock remains stable at 4°C for up to one week in sterile buffer with no significant activity loss. For longer storage, aliquot into single-use volumes and store at -20°C — freeze-thaw cycles cause peptide aggregation that reduces antimicrobial potency by 15% per cycle after three rounds. Never refreeze a thawed aliquot; prepare enough single-use aliquots to avoid repeated freeze-thaw.

The primary cause is ionic strength variation across culture media. Studies using low-salt Mueller-Hinton broth report IC50 values of 2–5 µM, while those using physiological-salt RPMI or DMEM report 20–100 µM for the same strain — a 10–50× difference. Serum presence, peptide purity, and counterion identity (TFA vs HCl salt) also contribute but to a lesser degree than salt concentration.

LL-37’s antimicrobial activity (membrane disruption) requires 5–50 µM and operates through carpet mechanism pore formation in bacterial membranes. The immune-modulating pathway (chemokine induction via FPRL1 receptor) activates at 0.5–2 µM — well below antimicrobial doses — and recruits neutrophils and monocytes without directly killing bacteria. These are mechanistically independent pathways that happen to use the same peptide.

Use 5–10% FBS unless your experimental design requires serum-free conditions. Serum contains protease inhibitors (alpha-1 antitrypsin, alpha-2 macroglobulin) that stabilise LL-37 and prevent degradation — serum-free medium allows rapid proteolysis and underestimates peptide activity by 3–5× compared to serum-containing conditions. If you must use serum-free medium, shorten your exposure time and increase peptide concentration accordingly.

Run a Bradford or BCA protein assay on your working stock and compare the measured concentration to your calculated concentration from the lyophilised powder weight. Commercial LL-37 purity ranges from 85–98%, so assuming 100% purity often leads to 2–15% underdosing. Also account for surface binding losses — diluting in siliconised tubes recovers 15–25% more peptide than standard polypropylene tubes after 2-hour incubation.

Human keratinocytes (HaCaT or primary NHEKs) are the standard model for LL-37 wound repair and scratch-wound migration assays. These cells express endogenous hCAP18 and respond to exogenous LL-37 through EGFR transactivation and VEGF upregulation at 1–5 µM. Use 10% FBS to stabilise the peptide and avoid cytotoxicity above 10 µM.

Bacterial biofilms produce extracellular DNA (eDNA) that binds cationic peptides like LL-37 and neutralises them before they reach bacterial membranes. Planktonic bacteria lack this protective matrix, so LL-37 accesses the membrane directly. To observe biofilm disruption in vitro, pre-treat with DNase I to degrade eDNA — without this step, LL-37 concentrations 10–20× higher than planktonic IC50 are required.

LL-37 binding to FPRL1 on monocytes and neutrophils triggers biphasic calcium flux — an immediate spike from intracellular stores followed by sustained influx from extracellular sources. Both phases are required for full IL-8 and MCP-1 induction; blocking extracellular calcium with EGTA reduces cytokine secretion by 60%. Most protocols don’t measure calcium flux, but it’s the mechanistic link between receptor binding and downstream signalling.

LL-37 remains stable and active across pH 6.5–8.0, with optimal antimicrobial activity at pH 7.4. Tris and HEPES buffers maintain peptide stability better than phosphate buffers, which chelate divalent cations required for membrane binding and reduce activity by 50% above 10mM phosphate concentration. If your assay uses PBS, verify the phosphate concentration and consider switching to HEPES-buffered saline for LL-37 experiments.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA